Refolding and kinetic characterization of the phosphodiesterase-8A catalytic domain

Protein Expression and Purification

Volumn 64, Issue 1, 2009, Pages 82-88

  Yan, Zier ^a   Wang, Huanchen ^b   Cai, Jiwen ^a   Ke, Hengming ^a,b  

^a SUN YAT SEN UNIVERSITY   (China)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Enzymatic kinetics; PDE8; Phosphodiesterases; Refolding

Indexed keywords

CYCLIC AMP PHOSPHODIESTERASE; PDE8A PROTEIN, HUMAN; PEPTIDE FRAGMENT;

AMINO ACID SEQUENCE; ARTICLE; CHEMISTRY; ENZYME ACTIVE SITE; ESCHERICHIA COLI; GENETICS; ISOLATION AND PURIFICATION; KINETICS; METABOLISM; MOLECULAR GENETICS; PH; PROTEIN RENATURATION; PROTEIN TERTIARY STRUCTURE; TEMPERATURE;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; AMINO ACID SEQUENCE; CATALYTIC DOMAIN; ESCHERICHIA COLI; HYDROGEN-ION CONCENTRATION; KINETICS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN RENATURATION; PROTEIN STRUCTURE, TERTIARY; TEMPERATURE;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; MAMMALIA;

EID: 57649094422     PISSN: 10465928     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pep.2008.10.005     Document Type: Article

References (50)

1. Antoni F. Molecular diversity of cyclic AMP signaling. Front. Neuroendocrinol. 21 (2000) 103-132
2. O'Neill J.S., Maywood E.S., Chesham J.E., Takahashi J.S., and Hastings M.H. CAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science 320 (2008) 949-953
3. Piper M., van Horck F., and Holt C. The role of cyclic nucleotides in axon guidance. Adv. Exp. Med. Biol. 621 (2007) 134-143
4. Zaccolo M., and Movsesian M.A. cAMP and cGMP signaling cross-talk: role of phosphodiesterases and implications for cardiac pathophysiology. Circ. Res. 100 (2007) 1569-1578
5. De Felice F.G., Wasilewska-Sampaio A.P., Barbosa A.C., Gomes F.C., Klein W.L., and Ferreira S.T. Cyclic AMP enhancers and Abeta oligomerization blockers as potential therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res. 4 (2007) 263-271
6. Horvath A., and Stratakis C.A. Unraveling the molecular basis of micronodular adrenal hyperplasia. Curr. Opin. Endocrinol. Diabetes Obes. 15 (2008) 227-233
7. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
8. Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 109 (2006) 366-398
9. Omori K., and Kotera J. Overview of PDEs and their regulation. Circ. Res. 100 (2007) 309-327
10. Conti M., and Beavo J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Ann. Rev. Biochem. 76 (2007) 481-511
11. Rotella D.P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 1 (2002) 674-682
12. Schrör K. The pharmacology of cilostazol. Diabetes Obes. Metab. 4 (2002) S14-19
13. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
14. Gales B.J., and Gales M.A. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms in men. Ann. Pharmacother. 42 (2008) 111-115
15. Houslay M.D., Schafer P., and Zhang K.Y. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov. Today 10 (2005) 1503-1519
16. Blokland A., Schreiber R., and Prickaerts J. Improving memory: a role for phosphodiesterases. Curr. Pharm. Des. 12 (2006) 2511-2523
17. Menniti F.S., Faraci W.S., and Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5 (2006) 660-670
18. Sharma R.K., Das S.B., Lakshmikuttyamma A., Selvakumar P., and Shrivastav A. Regulation of calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1): review. Int. J. Mol. Med. 18 (2006) 95-105
19. Galie N., Ghofrani H.A., Torbicki A., Barst R.J., Rubin L.J., Badesch D., Fleming T., Parpia T., Burgess G., Branzi A., Grimminger F., Kurzyna M., and Simonneau G. Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. 353 (2005) 2148-2157
20. Fisher D.A., Smith J.F., Pillar J.S., St. Denis S.H., and Cheng J.B. Isolation and characterization of PDE8A, a novel human cAMP-specific phosphodiesterase. Biochem. Biophys. Res. Commun. 246 (1998) 570-577
21. Soderling S.H., Bayuga S.J., and Beavo J.A. Cloning and characterization of a cAMP-specific cyclic nucleotide phosphodiesterase. Proc. Natl. Acad. Sci. USA 95 (1998) 8991-8996
22. Hayashi M., Matsushima K., Ohashi H., Tsunoda H., Murase S., Kawarada Y., and Tanaka T. Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3′, 5′-cyclic nucleotide phosphodiesterase. Biochem. Biophys. Res. Commun. 250 (1998) 751-756
23. Gamanuma M., Yuasa K., Sasaki T., Sakurai N., Kotera J., and Omori K. Comparison of enzymatic characterization and gene organization of cyclic nucleotide phosphodiesterase 8 family in humans. Cell Signal. 15 (2003) 565-574
24. Wang P., Wu P., Egan R.W., and Billah M.M. Human phosphodiesterase 8A splice variants: cloning, gene organization, and tissue distribution. Gene 280 (2001) 183-194
25. Hayashi M., Shimada Y., Nishimura Y., Hama T., and Tanaka T. Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene. Biochem. Biophys. Res. Commun. 297 (2002) 1253-1258
26. Kobayashi T., Gamanuma M., Sasaki T., Yamashita Y., Yuasa K., Kotera J., and Omori K. Molecular comparison of rat cyclic nucleotide phosphodiesterase 8 family: unique expression of PDE8B in rat brain. Gene 319 (2003) 21-31
27. Pérez-Torres S., Cortés R., Tolnay M., Probst A., Palacios J.M., and Mengod G. Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp. Neurol. 182 (2003) 322-334
28. Glavas N.A., Ostenson C., Schaefer J.B., Vasta V., and Beavo J.A. T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc. Natl. Acad. Sci. USA 98 (2001) 6319-6324
29. Dong H., Osmanova V., Epstein P.M., and Brocke S. Phosphodiesterase 8 (PDE8) regulates chemotaxis of activated lymphocytes. Biochem. Biophys. Res. Commun. 345 (2006) 713-719
30. Vasta V., Shimizu-Albergine M., and Beavo J.A. Modulation of Leydig cell function by cyclic nucleotide phosphodiesterase 8A. Proc. Natl. Acad. Sci. USA 103 (2006) 19925-19930
31. Dov A., Abramovitch E., Warwar N., and Nesher R. Diminished phosphodiesterase-8B potentiates biphasic insulin response to glucose. Endocrinology 149 (2008) 741-748
32. Horvath A., Mericq V., and Stratakis C.A. Mutation in PDE8B, a cyclic AMP-specific phosphodiesterase in adrenal hyperplasia. N. Engl. J. Med. 358 (2008) 750-752
33. Arnaud-Lopez L., Usala G., Ceresini G., Mitchell B.D., Pilia M.G., Piras M.G., Sestu N., Maschio A., Busonero F., Albai G., Dei M., Lai S., Mulas A., Crisponi L., Tanaka T., Bandinelli S., Guralnik J.M., Loi A., Balaci L., Sole G., Prinzis A., Mariotti S., Shuldiner A.R., Cao A., Schlessinger D., Uda M., Abecasis G.R., Nagaraja R., Sanna S., and Naitza S. Phosphodiesterase 8B gene variants are associated with serum TSH levels and thyroid function. Am. J. Hum. Genet. 82 (2008) 1270-1280
34. Crews S.T., and Fan C.M. Remembrance of things PAS: regulation of development by bHLH-PAS proteins. Curr. Opin. Genet. Dev. 9 (1999) 580-587
35. Wenger R.H., and Katschinski D.M. The hypoxic testis and post-meiotic expression of PAS domain proteins. Semin. Cell Dev. Biol. 16 (2005) 547-553
36. Wu P., and Wang P. Per-Arnt-Sim domain-dependent association of cAMP-phosphodiesterase 8A1 with IkappaB proteins. Proc. Natl. Acad. Sci. USA 101 (2004) 17634-17639
37. Ke H., and Wang H. Crystal structures of phosphodiesterases and implications on substrate specificity and inhibitor selectivity. Curr. Top. Med. Chem. 7 (2007) 391-403
38. Gasteiger E., Hoogland C., Gattiker A., Duvaud S., Wilkins M.R., Appel R.D., and Bairoch A. Protein identification and analysis tools on the ExPASy server. In: Walker J.M. (Ed). The Proteomics Protocols Handbook (2005), Humana Press, Clifton, UK 571-607
39. Wang H., Liu Y., Chen Y., Robinson H., and Ke H. Multiple elements jointly determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7. J. Biol. Chem. 280 (2005) 30949-30955
40. Fersht A. The basic equations of enzyme kinetics. Structure and Mechanism in Protein Science (1999), Freeman and Company, New York
41. Bolger G.B., Erdogan S., Jones R.E., Loughney K., Scotland G., Hoffmann R., Wilkinson I., Farrell C., and Houslay M.D. Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene. Biochem. J. 328 (1997) 539-548
42. Michaeli T., Bloom T.J., Martins T., Loughney K., Ferguson K., Riggs M., Rodgers L., Beavo J.A., and Wigler M. Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevisiae. J. Biol. Chem. 268 (1993) 12925-12932
43. Huai Q., Wang H., Zhang W., Colman R., Robinson H., and Ke H. Crystal structure of phosphodiesterase 9 shows orientation variation of inhibitor 3-isobutyl-1-methylxanthine binding. Proc. Natl. Acad. Sci. USA 101 (2004) 9624-9629
44. Wang H., Liu Y., Hou J., Zheng M., Robinson H., and Ke H. Structural insight into substrate specificity of phospodiesterase 10. Proc. Natl. Acad. Sci. USA 104 (2007) 5782-5787
45. Soderling S.H., Bayuga S.J., and Beavo J.A. Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc. Natl. Acad. Sci. USA 96 (1999) 7071-7076
46. Wang H., Yan Z., Yang S., Cai J., Robinson H., and Ke H. Kinetic and structural studies of phosphodiesterase-8A and implication on the inhibitor selectivity. Biochemistry (2008) [Epub ahead of print]
47. Xu R.X., Hassell A.M., Vanderwall D., Lambert M.H., Holmes W.D., Luther M.A., Rocque W.J., Milburn M.V., Zhao Y., Ke H., and Nolte R.T. Atomic structure of PDE4: insight into phosphodiesterase mechanism and specificity. Science 288 (2000) 1822-1825
48. Huai Q., Colicelli J., and Ke H. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis. Biochemistry 42 (2003) 13220-13226
49. Fisher D.A., Smith J.F., Pillar J.S., St Denis S.H., and Cheng J.B. Isolation characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem. 273 (1998) 15559-15564
50. Wang P., Wu P., Egan R.W., and Billah M.M. Identification, characterization of a new human type 9 cGMP-specific phosphodiesterase splice variant (PDE9A5). Differential tissue distribution, subcellular localization of PDE9A, variants. Gene 314 (2003) 15-27